当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

Abstract：

:Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards improving prognosis. We defined a gene signature that accurately discriminates between prednisolone-resistant and prednisolone-sensitive MLL-rearranged infant ALL patient samples. In the current study, we applied Connectivity Map analysis to perform an in silico screening for agents capable of reversing the prednisolone-resistance profile and induce sensitivity. These analyses revealed that LY294002, a PI3K inhibitor, would potentially fulfill this task. Subsequent validation experiments demonstrated that indeed LY294002, and other known PI3K inhibitors, markedly sensitized otherwise resistant MLL-rearranged ALL cells to prednisolone in vitro. Using quantitative RT-PCR analyses, we validated the modulating effects of the PI3K inhibitors on the expression of the genes present in our prednisolone-resistance profile. Interestingly, prednisolone-sensitizing actions may be mediated by inhibition of FCGR1B. Moreover, only high-level expression of FCGR1B showed to be predictive for a poor prognosis and shRNA-mediated knock-down of FCGR1B led to in vitro prednisolone sensitization. Thus, implementing FDA-approved PI3K inhibitors in current treatments may potentially improve the GC response and prognosis in patients with MLL-rearranged ALL.

journal_name

Leukemia

journal_title

Leukemia

authors

Spijkers-Hagelstein JA,Pinhanços SS,Schneider P,Pieters R,Stam RW

doi

10.1038/leu.2013.245

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

761-9

issue

4

eissn

0887-6924

issn

1476-5551

pii

leu2013245

journal_volume

28

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.

    abstract：:Mantle cell lymphoma represent a clinicopathologically distinct entity of malignant non-Hodgkin's lymphoma (NHL) and are characterized by a specific chromosomal translocation t(11;14)(q13;q32) involving the cyclin D1 gene also designated as bcl-1/PRAD1 gene on chromosome 11 and the heavy chain immunoglobulin joining r...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401172

    authors： Pott C,Tiemann M,Linke B,Ott MM,von Hofen M,Bolz I,Hiddemann W,Parwaresch R,Kneba M

    更新日期：1998-10-01 00:00:00

  • Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.

    abstract：:The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase sig...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.166

    authors： Welsh SJ,Churchman ML,Togni M,Mullighan CG,Hagman J

    更新日期：2018-01-01 00:00:00

  • Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia.

    abstract：:To clarify the clinical and biological significance of beta 2-microglobulin (beta 2-M) in serum of adult T cell leukemia (ATL) associated with human lymphotropic virus type-I (HTLV-I), beta 2-M was measured in 52 patients with ATL (acute ATL, 35 patients; lymphoma ATL, two patients; chronic ATL, 12 patients; smolderin...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sadamori N,Mine M,Hakariya S,Ichiba M,Kawachi T,Itoyama T,Nakamura H,Tomonaga M,Hayashi K

    更新日期：1995-04-01 00:00:00

  • Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.

    abstract：:To address the prognostic value of minimal residual disease (MRD) before unrelated cord blood transplantation (UCBT) in children with acute lymphoblastic leukemia (ALL), we analyzed 170 ALL children transplanted in complete remission (CR) after myeloablative conditioning regimen. In all, 72 (43%) were in first CR (CR1...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2012.123

    authors： Ruggeri A,Michel G,Dalle JH,Caniglia M,Locatelli F,Campos A,de Heredia CD,Mohty M,Hurtado JM,Bierings M,Bittencourt H,Mauad M,Purtill D,Cunha R,Kabbara N,Gluckman E,Labopin M,Peters C,Rocha V

    更新日期：2012-12-01 00:00:00

  • GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia.

    abstract：:Fourteen patients (M/F, 6/8; age, 48/23-64 yrs) with relapsing or primary resistant intermediate-high grade non-Hodgkin lymphomas were treated with ARA-C (2 g/m2 x 4 on days 1 and 2), DDP (100 mg/m2 96 hr infusion) and VP-16 (150 mg/m2 on days 1, 2 and 3). GM-CSF or placebo was administered from the 5th day until neut...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Liberati AM,Cinieri S,Schippa M,Di Clemente F,Filippo S,Grignani F

    更新日期：1991-01-01 00:00:00

  • The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

    abstract：:The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2015.113

    authors： Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

    更新日期：2015-08-01 00:00:00

  • Induction of centrosome and chromosome aberrations by imatinib in vitro.

    abstract：:Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403861

    authors： Fabarius A,Giehl M,Frank O,Duesberg P,Hochhaus A,Hehlmann R,Seifarth W

    更新日期：2005-09-01 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract：:Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.194

    authors： Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期：2013-12-01 00:00:00

  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

    abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.176

    authors： Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

    更新日期：2014-02-01 00:00:00

  • BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

    abstract：:Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia. However, patients with a potential for cure are at risk of severe acute and late adverse effects of treatment. Furthermore, in 25-30% of pati...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1038/sj.leu.2402489

    authors： Kamps WA,Bökkerink JP,Hakvoort-Cammel FG,Veerman AJ,Weening RS,van Wering ER,van Weerden JF,Hermans J,Slater R,van den Berg E,Kroes WG,van der Does-van den Berg A

    更新日期：2002-06-01 00:00:00

  • Electric field-mediated gene transfer into K562 cells: optimization of parameters affecting efficiency.

    abstract：:Since hemopoietic cells are refractory to transfection by conventional chemical means, we have developed a reliable and efficient gene transfer system for K562 cells which uses electric field-mediated gene transfer (EFMGT). EFMGT involves the exposure of cells in suspension to an electric field which transiently allow...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Croaker GM,Wass EJ,Iland HJ

    更新日期：1990-07-01 00:00:00

  • Chromosomal rearrangement on chromosome 11q14-q21 in T cell acute lymphoblastic leukemia.

    abstract：:Deletion and translocation involving the bands 11q14 and 11q21 have been detected in five patients with T cell acute lymphoblastic leukemia (ALL). The breakpoint on chromosome 11 was on the same band as that previously described in some acute nonlymphocytic leukemias: monocytic or myelomocytic. The existence of a new ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Berger R,Le Coniat M,Derré J,Vecchione D,Chen SJ

    更新日期：1989-08-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract：:We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404653

    authors： Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期：2007-06-01 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403667

    authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期：2005-04-01 00:00:00

  • Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

    abstract：:Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/s41375-018-0055-7

    authors： Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

    更新日期：2018-05-01 00:00:00

  • Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

    abstract：:Fresh and/or frozen bone marrow cells from five healthy individuals and seven patients with myeloid leukemia were studied using growth factors and a cytogenetic technique which allows simultaneous analysis of karotype and cell lineage. Cell lineages were identified using monoclonal antibodies in an alkaline phosphatas...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Keinänen M,Bloomfield CD,Machnicki J,Griffin JD,de la Chapelle A

    更新日期：1989-06-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract：:Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.197

    authors： Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期：2013-12-01 00:00:00

  • Human stem cell factor (c-kit ligand) induces an autocrine loop of growth in a GM-CSF-dependent megakaryocytic leukemia cell line.

    abstract：:The M07e megakaryoblastic leukemia cell line is strictly dependent on either interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) for continuous growth. This study shows that recombinant human stem-cell factor (rhSCF) can completely replace these lymphokines in supporting the continued pro...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kiss C,Cesano A,Zsebö KM,Clark SC,Santoli D

    更新日期：1993-02-01 00:00:00

  • The regulation of hematopoiesis in max 41 transgenic mice with sustained excess granulopoiesis.

    abstract：:max 41 transgenic mice consistently exhibit elevated numbers of mature granulocytes and monocytes in the peripheral blood and of immature and mature cells of these lineages in the marrow, spleen, lymph nodes and liver. The immature populations are not autonomous and exhibit a normal quantitative responsiveness to prol...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Metcalf D,Roberts AW,Willson TA

    更新日期：1996-02-01 00:00:00

  • Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.

    abstract：:This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Frassoni F,Carella AM

    更新日期：1996-06-01 00:00:00

  • Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia.

    abstract：:We used fluorescence in situ hybridization (FISH) to metaphase chromosomes with BCR and ABL cosmid probes in conjunction with the polymerase chain reaction (PCR) to study the mechanism by which the ABL proto-oncogene is inserted into a morphologically normal chromosome 22 in patients with Ph-negative chronic myeloid l...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lazaridou A,Chase A,Melo J,Garicochea B,Diamond J,Goldman J

    更新日期：1994-03-01 00:00:00

  • Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

    abstract：:Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404681

    authors： Jiménez M,Ercilla G,Martínez C

    更新日期：2007-08-01 00:00:00

  • Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

    abstract：:Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma. The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combin...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.218

    authors： Carney DA,Westerman DA,Tam CS,Milner A,Prince HM,Kenealy M,Wolf M,Januszewicz EH,Ritchie D,Came N,Seymour JF

    更新日期：2010-12-01 00:00:00

  • IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

    abstract：:The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG tr...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2015.134

    authors： Clappier E,Grardel N,Bakkus M,Rapion J,De Moerloose B,Kastner P,Caye A,Vivent J,Costa V,Ferster A,Lutz P,Mazingue F,Millot F,Plantaz D,Plat G,Plouvier E,Poirée M,Sirvent N,Uyttebroeck A,Yakouben K,Girard S,Dastu

    更新日期：2015-11-01 00:00:00

  • Significance of chemokine receptor expression in aggressive NK cell leukemia.

    abstract：:Natural killer (NK) cell-type lymphoproliferative diseases of granular lymphocytes can be subdivided into aggressive NK cell leukemia (ANKL) and chronic NK cell lymphocytosis (CNKL). One reason for the poor outcome in ANKL is leukemic infiltration into multiple organs. The mechanisms of cell trafficking associated wit...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403732

    authors： Makishima H,Ito T,Asano N,Nakazawa H,Shimodaira S,Kamijo Y,Nakazawa Y,Suzuki T,Kobayashi H,Kiyosawa K,Ishida F

    更新日期：2005-07-01 00:00:00

  • Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells.

    abstract：:Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Dickinson JL,Antalis TM

    更新日期：1993-06-01 00:00:00

  • High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.

    abstract：:We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404404

    authors： Skärby TV,Anderson H,Heldrup J,Kanerva JA,Seidel H,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

    更新日期：2006-11-01 00:00:00

  • Trial of IFN or STI571 before proceeding to allografting for CML?

    abstract：:Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401874

    authors： Hehlmann R

    更新日期：2000-09-01 00:00:00

  • L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

    abstract：:The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leuke...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.338

    authors： Rosilio C,Nebout M,Imbert V,Griessinger E,Neffati Z,Benadiba J,Hagenbeek T,Spits H,Reverso J,Ambrosetti D,Michiels JF,Bailly-Maitre B,Endou H,Wempe MF,Peyron JF

    更新日期：2015-06-01 00:00:00

  • Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.

    abstract：:Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell alloreactivity and the role of NK recovery in sibling SCT are not well defined. NK cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404892

    authors： Savani BN,Mielke S,Adams S,Uribe M,Rezvani K,Yong AS,Zeilah J,Kurlander R,Srinivasan R,Childs R,Hensel N,Barrett AJ

    更新日期：2007-10-01 00:00:00